Indications for Starting Steroids in Henoch-Schönlein Purpura (HSP)
Steroids should be started in HSP for severe gastrointestinal manifestations (severe abdominal pain, gastrointestinal hemorrhage) and for established HSP nephritis with significant proteinuria or nephritic/nephrotic features, but NOT routinely for prevention of renal disease in uncomplicated HSP.
Clinical Algorithm for Steroid Initiation
1. Severe Gastrointestinal Manifestations (Start Steroids)
- Severe, disabling abdominal pain that limits daily activities
- Gastrointestinal hemorrhage (hematemesis, melena, hematochezia)
- Risk of or confirmed intussusception
Early corticosteroid exposure significantly reduces the need for abdominal surgery (HR 0.39), endoscopy (HR 0.27), and abdominal imaging (HR 0.50) 1. Steroids reduce the intensity of abdominal pain (pain score 2.5 vs 4.8, p=0.029) and increase odds of pain resolution within 24 hours 2, 3. While two studies showed potential reduction in intussusception risk, this did not reach statistical significance 4.
Dosing for GI manifestations: Prednisone 1-2 mg/kg/day orally for 1-2 weeks, then taper over 1-2 weeks 3, 5.
2. Established HSP Nephritis (Start Steroids)
Start steroids when renal involvement includes:
- Nephrotic syndrome (proteinuria >3.5 g/day AND serum albumin <30 g/L)
- Nephritic syndrome (hematuria with proteinuria, hypertension, reduced GFR)
- Persistent significant proteinuria (>1 g/day for >3 months despite ACE-I/ARB therapy)
- Crescentic glomerulonephritis on biopsy (ISKDC grade III or higher)
The evidence shows steroids are effective in treating established renal disease—61% of prednisone patients had resolution of renal symptoms versus 34% of placebo patients (difference 27%, p=0.024) 3. Based on similarities with IgA nephropathy, experts recommend corticosteroids to prevent long-term kidney injury in established nephritis 6, 7, 5.
Dosing for nephritis: Prednisone 1-2 mg/kg/day (maximum 60-80 mg/day) for 4-12 weeks, then gradual taper. Consider pulse methylprednisolone (15-20 mg/kg/day for 3 days) for severe crescentic disease 6, 8.
3. DO NOT Start Steroids (Critical Pitfall)
Do NOT use steroids routinely for prevention of renal disease in uncomplicated HSP. This is the most important clinical distinction.
Multiple high-quality RCTs demonstrate that early prednisone therapy does NOT prevent the development of renal involvement 9, 3, 4. A Cochrane review found no significant difference in persistent kidney disease at any timepoint (RR 0.74,95% CI 0.42-1.32) with prophylactic steroids 9. The largest placebo-controlled trial (171 patients) showed no difference in renal involvement at 1 year (3/21 prednisone vs 2/19 placebo, p=1.0) 4.
Uncomplicated HSP includes:
- Palpable purpura alone
- Mild joint pain/arthralgia
- Mild abdominal discomfort not requiring hospitalization
- Isolated microscopic hematuria without proteinuria
- Proteinuria <1 g/day with normal renal function
4. Severe Joint Manifestations (Consider Steroids)
While less commonly requiring steroids, prednisone reduces joint pain intensity (4.6 vs 7.3, p=0.030) 3. Consider short course (1-2 weeks) for:
- Severe arthritis preventing ambulation
- Multiple large joint involvement with significant functional impairment
Key Clinical Nuances
Timing matters: When steroids ARE indicated, early administration is more effective. For GI manifestations, benefits are seen within 24-48 hours 1, 2. For nephritis, treatment should begin once diagnosis is confirmed by urinalysis or biopsy 6, 8.
ACE-I/ARB role: For HSP nephritis, start ACE inhibitors or ARBs as first-line therapy for proteinuria <3 g/day before considering steroids 5. However, one protocol showed equivalent efficacy using steroids and immunosuppressants without ACE-I/ARB in the acute phase, achieving 96% proteinuria resolution 8. The traditional approach combines both.
Immunosuppression escalation: For severe HSP nephritis (ISKDC grade III-V) not responding to steroids alone, add cyclophosphamide, azathioprine, mycophenolate mofetil, or cyclosporine in consultation with pediatric nephrology 6, 5. Rituximab shows promise for refractory cases 6.
Common pitfall: Physicians often prescribe steroids at HSP presentation hoping to prevent renal disease—this is NOT supported by evidence and exposes patients to unnecessary steroid toxicity 9, 4, 7. The self-limited nature of HSP (94% resolution without intervention) and low rate of severe renal disease (<2%) do not justify prophylactic immunosuppression 9, 5.
Monitoring: All HSP patients require urinalysis monitoring for 6-12 months regardless of steroid use, as renal involvement can develop weeks to months after initial presentation 7, 5.